ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (Liso-Cel) As Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Clinical Lymphoma Myeloma and Leukemia（2024）
Key words
ABCL,lisocabtagene maraleucel,follicular lymphoma,bridging therapy,POD24,chimeric antigen receptor T-cell therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined